Trial Profile

A Phase 1/2, Randomized, Observer-Blind, Controlled, Dose-Ranging Study of mRNA-1608, an HSV-2 Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 16 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Meningococcal vaccine group B OMV Novartis (Primary) ; MRNA-1608 (Primary)
Indications Herpes genitalis; Neisseria infections
Focus Adverse reactions; Proof of concept
Sponsors Moderna Therapeutics

08 May 2025 Status changed from active, no longer recruiting to completed.
24 Sep 2024 Planned End Date changed from 4 Jun 2025 to 11 Apr 2025.
24 Sep 2024 Planned primary completion date changed from 4 Jun 2025 to 11 Apr 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com